Question for written answer E-004350/2019
to the Commission
Rule 138
Joanna Kopcińska (ECR)

Subject: Regulation of the European Parliament and of the Council on health technology assessment and amending Directive 2011/24/EU

The outgoing Commission proposed that national health technology assessments (HTAs) should be phased out and an EU-wide system set up for the assessment of new medicines, medical equipment, and diagnostic and medical treatment methods. Results would then be made available to the national authorities of the Member States. This proposal met with strong opposition from a number of Member States in the Council, who questioned the need for the change on the basis of the subsidiarity principle.

1. Should the Commission be insisting at all that the proposal be maintained?

2. Why does the Commission want to propose a common pricing and reimbursement system for health technologies at EU level when the assessment and ratio of costs for health-related interventions are different in each Member State (depending on the state of the economy and the legislation in force), and HTAs provide a scientific basis for decisions on the pricing and reimbursement system for health technologies, which are also dependent on economic indicators?